FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer

The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news